This provider's Medicare activity is concentrated in retina-focused procedures and high-volume established-patient visits: J0178 (aflibercept injection) accounts for $244.6K or 51.1% of Medicare revenue, 92014 (established comprehensive eye exam) accounts for $104K or 21.7%, and J2777 (faricimab) contributes $55.7K or 11.6%; the top three codes together represent 84.4% of the provider's total Medicare revenue. The code mix (intravitreal drug injections J0178 and J2777, retina imaging 92134, and frequent established-patient exams 92014) is consistent with an ophthalmology practice that manages chronic posterior-segment disease and delivers frequent in-office injections and follow-up visits. The scale of lifetime Medicare revenue is modest at $478.9K, indicating a relatively small independent practice footprint in Medicare dollars despite the high concentration in a few high-value services. The provider appears effectively single‑payer from a claims perspective: no Medicaid billing is on file, so Medicare represents essentially the entire public-payer footprint and creates concentrated exposure to Medicare reimbursement dynamics. Competitive standing is mixed by code: 92014 ranks notably above typical national volume (97th percentile), signaling strong office visit throughput relative to peers, while J0178 and J2777 are described as typical, unremarkable volumes nationally, indicating the provider is not a dominant national injector for those drugs. Several other procedure codes (92134, 67028, J9035) contribute smaller shares and are also labeled typical, unremarkable volume, so aside from high visit volume the provider does not display multiple national outlier positions. The provider's NPI was enumerated on 2006-06-12 (~20 years ago), indicating long tenure in the Medicare program, which supports the interpretation that current patterns reflect an established clinical workflow rather than a short-term billing anomaly. The revenue concentration (84.4% in the top three codes and 51.1% from a single code J0178) suggests operational and financial sensitivity to changes in reimbursement, utilization of these drugs, or shifts in clinical practice that affect intravitreal injection volume or drug selection.